Literature DB >> 26552804

Does Chronic Corticosteroid Use Increase Risks of Readmission, Thromboembolism, and Revision After THA?

Matthew R Boylan1, Dean C Perfetti1, Randa K Elmallah2, Viktor E Krebs3, Carl B Paulino1, Michael A Mont4.   

Abstract

BACKGROUND: Systemic corticosteroids are commonly used to treat autoimmune and inflammatory diseases, but they can be associated with various musculoskeletal problems and disorders. There currently is a limited amount of data describing the postoperative complications of THA associated specifically with chronic corticosteroid use. QUESTIONS/PURPOSES: For chronic corticosteroid users undergoing THA, we asked: (1) What is the risk of hospital readmission at 30 and 90 days after surgery? (2) What is the risk of venous thromboembolism at 30 and 90 days after surgery? (3) What is the risk of revision hip arthroplasty at 12 and 24 months after surgery?
METHODS: We identified patients in the Statewide Planning and Research Cooperative System who underwent primary THA between January 2003 and December 2010. This database provides hospital discharge abstracts for all admissions in the state of New York each year. We used propensity scores to three-to-one match the 402 chronic corticosteroid users with a comparison cohort of 1206 patients according to age, sex, race, comorbidity score, year of surgery, and hip osteonecrosis. The risk of each outcome was compared between chronic corticosteroid users and the matched cohort. Because multiple comparisons were made, we considered p less than 0.008 as statistically significant.
RESULTS: Readmission was more common for corticosteroid users at 30 days (odds ratio [OR], 1.45; 95% CI, 1.14-1.85; p = 0.003) and 90 days (OR, 1.37; 95% CI, 1.09-1.73; p = 0.007). Venous thromboembolism was not more frequent in corticosteroid users at 30 days (OR, 2.39; 95% CI, 1.08-5.26; p = 0.031) or 90 days (OR, 1.91; 95% CI, 1.03-3.53; p = 0.039). Revision arthroplasty was more common in corticosteroid users at 12 months (OR, 2.49; 95% CI, 1.35-4.59; p = 0.004), but not 24 months (OR, 2.04; 95% CI, 1.19-3.50; p = 0.010).
CONCLUSIONS: After THA, chronic corticosteroid use is associated with an increased risk of readmission at 30 and 90 days and revision hip arthroplasty at 12 months in corticosteroid users. Patients and providers should discuss these risks before surgery. Insurers should consider incorporating chronic corticosteroid use as a comorbidity in bundled payments for THA, since this patient population is more likely to return to their provider for care during the postoperative period. LEVEL OF EVIDENCE: Level III, therapeutic study.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26552804      PMCID: PMC4746147          DOI: 10.1007/s11999-015-4605-2

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  26 in total

1.  Increased risk of complications following total joint arthroplasty in patients with rheumatoid arthritis.

Authors:  Bheeshma Ravi; Ruth Croxford; Simon Hollands; J Michael Paterson; Earl Bogoch; Hans Kreder; Gillian A Hawker
Journal:  Arthritis Rheumatol       Date:  2014-02       Impact factor: 10.995

2.  What are the risk factors for infection in hemiarthroplasties and total hip arthroplasties?

Authors:  José Cordero-Ampuero; Marisol de Dios
Journal:  Clin Orthop Relat Res       Date:  2010-12       Impact factor: 4.176

3.  Total hip arthroplasty in patients with chronic autoimmune inflammatory arthroplasties.

Authors:  Roland Weng Wah Chong; Choon Seng Chong; Choon Hin Lai
Journal:  Int J Rheum Dis       Date:  2010-08       Impact factor: 2.454

4.  The long-term outcome of hip replacement in adults with juvenile idiopathic arthritis: the influence of steroids and methotrexate.

Authors:  A Malviya; L C Walker; P Avery; S Osborne; D J Weir; H E Foster; D J Deehan
Journal:  J Bone Joint Surg Br       Date:  2011-04

5.  Steroid modulation of cytokine release and desmosine levels in bilateral total knee replacement: a prospective, double-blind, randomized controlled trial.

Authors:  Kethy M Jules- Elysee; Sarah E Wilfred; Stavros G Memtsoudis; David H Kim; Jacques T YaDeau; Michael K Urban; Michael L Lichardi; Alexander S McLawhorn; Thomas P Sculco
Journal:  J Bone Joint Surg Am       Date:  2012-12-05       Impact factor: 5.284

6.  Risk factors for early revision after primary total hip arthroplasty in Medicare patients.

Authors:  Kevin J Bozic; Edmund Lau; Kevin Ong; Vanessa Chan; Steven Kurtz; Thomas P Vail; Harry E Rubash; Daniel J Berry
Journal:  Clin Orthop Relat Res       Date:  2014-02       Impact factor: 4.176

Review 7.  Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options.

Authors:  R N J De Nijs
Journal:  Minerva Med       Date:  2008-02       Impact factor: 4.806

8.  Effects of cyclosporin A and dexamethasone on haemostatic and vasoactive functions of vascular endothelial cells.

Authors:  L Q Huang; J A Whitworth; C N Chesterman
Journal:  Blood Coagul Fibrinolysis       Date:  1995-07       Impact factor: 1.276

9.  Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis.

Authors:  Tim Bongartz; Christine S Halligan; Douglas R Osmon; Megan S Reinalda; William R Bamlet; Cynthia S Crowson; Arlen D Hanssen; Eric L Matteson
Journal:  Arthritis Rheum       Date:  2008-12-15

10.  Risk factors for infection following total joint arthroplasty in rheumatoid arthritis.

Authors:  Ranjani Somayaji; Cheryl Barnabe; Liam Martin
Journal:  Open Rheumatol J       Date:  2013-11-29
View more
  6 in total

1.  Evaluating the Association between Anesthesia Type and Postoperative Complications for Patients Receiving Total Ankle Arthroplasty.

Authors:  Frank R Chen; Theodore Quan; Joseph E Manzi; Alex Gu; Chapman Wei; Sean Tabaie; Marc Chodos; Cary B Chapman; Kane O Pryor; Jiabin Liu
Journal:  Iowa Orthop J       Date:  2022-06

2.  A nationwide analysis on the effects of chronic obstructive pulmonary disease following primary total shoulder arthroplasty for glenohumeral osteoarthritis.

Authors:  Brandon Amirian; Kyrillos M Akhnoukh; Asad M Ashraf; Samuel J Swiggett; Francis E Rosato; Rushabh M Vakharia; Ramin Sadeghpour; Afshin E Razi
Journal:  Shoulder Elbow       Date:  2021-02-25

3.  Reasons and risk factors for ninety day re-admission following primary total knee arthroplasty in a high-volume centre.

Authors:  Sami A Saku; Rami Madanat; Tatu J Mäkinen
Journal:  Int Orthop       Date:  2017-10-25       Impact factor: 3.075

4.  Laponite intercalated biomimetic multilayer coating prevents glucocorticoids induced orthopedic implant failure.

Authors:  Zhe Liu; Qian Tang; Ruo-Tao Liu; Ming-Zhao Yu; Hao Peng; Chang-Qing Zhang; Zhen-Zhong Zhu; Xiao-Juan Wei
Journal:  Bioact Mater       Date:  2022-09-26

5.  Association between Exposure to Benzodiazepines and Related Drugs and Survivorship of Total Hip Replacement in Arthritis: A Population-Based Cohort Study of 246,940 Patients.

Authors:  Dan Beziz; Sandrine Colas; Cédric Collin; Rosemary Dray-Spira; Mahmoud Zureik
Journal:  PLoS One       Date:  2016-05-24       Impact factor: 3.240

6.  Chronic Corticosteroid Use as a Risk Factor for Perioperative Complications in Patients Undergoing Total Joint Arthroplasty.

Authors:  Haley Kittle; Andrew Ormseth; Michael J Patetta; Anshum Sood; Mark H Gonzalez
Journal:  J Am Acad Orthop Surg Glob Res Rev       Date:  2020-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.